Fatty Liver

Arteriosclerosis, Thrombosis, and Vascular Biology - Tập 28 Số 1 - Trang 27-38 - 2008
Anna Kotronen1, Hannele Yki‐Järvinen1
1From the Department of Medicine, Division of Diabetes (A.K., H.Y.-J.), University of Helsinki, and Minerva Medical Research Institute (A.K.), Helsinki, Finland.

Tóm tắt

Although the epidemic of obesity has been accompanied by an increase in the prevalence of the metabolic syndrome, not all obese develop the syndrome and even lean individuals can be insulin resistant. Both lean and obese insulin resistant individuals have an excess of fat in the liver which is not attributable to alcohol or other known causes of liver disease, a condition defined as nonalcoholic fatty liver disease (NAFLD) by gastroenterologists. The fatty liver is insulin resistant. Liver fat is highly significantly and linearly correlated with all components of the metabolic syndrome independent of obesity. Overproduction of glucose, VLDL, CRP, and coagulation factors by the fatty liver could contribute to the excess risk of cardiovascular disease associated with the metabolic syndrome and NAFLD. Both of the latter conditions also increase the risk of type 2 diabetes and advanced liver disease. The reason why some deposit fat in the liver whereas others do not is poorly understood. Individuals with a fatty liver are more likely to have excess intraabdominal fat and inflammatory changes in adipose tissue. Intervention studies have shown that liver fat can be decreased by weight loss, PPARγ agonists, and insulin therapy.

Từ khóa


Tài liệu tham khảo

10.1053/euhj.2001.2889

10.1136/bmj.289.6454.1257

10.2337/diab.37.12.1595

10.1016/S0140-6736(05)67402-8

10.1016/S0735-1097(02)02051-X

10.1016/S1043-2760(00)00309-X

10.2337/diabetes.49.5.749

10.1210/jcem.87.7.8638

10.1007/s00125-005-0125-z

10.1007/s001250050700

10.2337/dc06-1414

10.1161/circulationaha.105.169404

10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

10.1053/jhep.2003.50193

10.1055/s-2001-12925

10.1002/jmri.1880050311

10.1016/0730-725X(94)92543-7

10.1152/ajpendo.1999.276.5.E977

10.1002/hep.20701

10.1152/ajpendo.00064.2004

10.1007/s00125-004-1460-1

10.1016/S0730-725X(96)00224-X

10.1055/s-2001-12930

10.1111/j.1651-2227.2007.00186.x

Kotronen A Westerbacka J Bergholm R Pietilainen KH Yki-Jarvinen H. Liver Fat in the Metabolic Syndrome. J Clin Endocrinol Metab. In press.

10.1002/hep.20466

10.1055/s-2005-861411

10.1046/j.1537-2995.1987.27587320539.x

Wasastjerna C, Reissell P, Karjalainen J, Ekelund P. Fatty liver in diabetes. A cytological study. Acta Med Scand. 1972; 191: 225–228.

Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord. 1995; 19: 841–845.

10.3168/jds.S0022-0302(98)75630-9

10.2337/diab.33.5.486

10.1152/ajpendo.00133.2006

10.1172/JCI24930

10.1073/pnas.96.24.13656

10.1074/jbc.274.42.30028

10.1111/j.1464-5491.2006.01858.x

10.1053/j.gastro.2006.03.019

10.1111/j.1365-2265.2006.02466.x

10.1210/jc.2004-2240

10.1007/s00535-006-1790-5

10.1111/j.1464-5491.2005.01646.x

10.1038/sj.ijo.0802519

10.3346/jkms.2005.20.3.421

10.1152/ajpendo.00117.2003

10.1016/S0950-351X(05)80239-3

10.1161/atvb.17.7.1454

Nikkila EA, Taskinen MR. Relation between H.D.L.-cholesterol levels and triglyceride metabolism. Lancet. 1978; 2: 892.

10.1172/JCI117242

Bergholm R, Westerbacka J, Vehkavaara S, Seppala-Lindroos A, Goto T, Yki-Jarvinen H. Insulin sensitivity regulates autonomic control of heart rate variation independent of body weight in normal subjects. J Clin Endocrinol Metab. 2001; 86: 1403–1409.

10.1097/00004872-199006000-00001

10.2174/1566524053766086

10.3748/wjg.v12.i48.7725

10.1056/NEJM199902113400607

10.1210/er.2005-0005

10.1002/hep.21327

Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006; 40 (3 Suppl 1): S11–S116.

10.1136/gut.2006.091454

10.1002/hep.21496

10.1111/j.1478-3231.2005.01209.x

10.1111/j.1572-0241.2003.07486.x

10.1542/peds.2006-1212

10.1073/pnas.0608537103

10.5551/jat.12.295

10.1080/00365520500264953

10.1210/jcem.84.5.5661

10.7326/0003-4819-143-10-200511150-00009

10.1002/dmrr.666

10.2337/diabetes.54.11.3140

Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988; 31: 798–805.

10.2337/diabetes.51.6.1889

10.2337/diabetes.53.10.2623

10.2337/diacare.21.5.732

10.2337/diacare.27.6.1427

10.1007/s00125-003-1036-5

10.1373/49.8.1358

10.1210/jc.2004-0505

10.2337/db06-1256

10.1016/S1262-3636(07)70229-X

10.2337/diacare.28.7.1757

10.2337/diacare.28.11.2812

10.1016/j.atherosclerosis.2006.04.006

10.1016/j.atherosclerosis.2006.01.010

Targher G Bertolini L Padovani R Rodella S Tessari R Zenari L Day C Arcaro G Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;

10.7861/clinmedicine.6-1-19

10.1016/0016-5085(94)90235-6

10.1016/0046-8177(89)90249-9

10.1002/hep.1840110114

Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38: 420–427.

10.1016/S1542-3565(04)00440-9

10.1194/jlr.R600018-JLR200

10.1172/JCI23621

10.1172/JCI21047

10.1079/BJN2001514

10.1016/S1262-3636(07)70061-7

Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, Miyagi I, Enjoji M. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2005; 16: 631–635.

10.1002/hep.20838

10.1038/labinvest.3700374

10.1016/j.bbrc.2005.12.121

10.1111/j.1478-3231.2006.01401.x

10.1016/j.jhep.2006.10.021

10.1172/JCI200319246

10.1172/JCI200319451

10.2337/diabetes.54.8.2305

10.1097/01.mco.0000172571.41149.52

10.1194/jlr.M500294-JLR200

Makkonen J Westerbacka J Kolak M Sutinen J Corner A Hamsten A Fisher RM Yki-Jarvinen H. Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue but not in cultured monocyte-derived macrophages is associated with liver fat in human obesity. Int J Obes (Lond). 2007.

10.2337/diabetes.54.8.2277

Kolak M Westerbacka J Velagapudi VR Wågsäter D Yetukuri L Makkonen J Rissanen A Hakkinen AM Lindell M Hamsten A Eriksson P Fisher RM Oresic M Yki-Jarvinen H. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes. In press.

10.1172/JCI26498

10.1172/JCI24335

10.1038/nm1166

Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 2000; 26: 98–106.

10.2337/diabetes.52.3.701

10.1093/ajcn/84.2.304

10.1016/S0168-8278(97)80287-5

10.1111/j.1365-2036.2004.02153.x

10.1016/j.cgh.2006.02.004

10.1038/414782a

10.1152/ajpendo.00557.2004

10.1152/ajpendo.00381.2004

Valtuena S Pellegrini N Ardigo D Del Rio D Numeroso F Scazzina F Monti L Zavaroni I Brighenti F. Dietary glycemic index and liver steatosis. Am J Clin Nutr. 84:136–142 2006; quiz 268–269.

10.1210/jc.2004-1983

10.1093/ajcn/84.6.1374

10.2337/dc06-2032

10.2337/dc05-2565

10.1056/NEJMoa060326

10.2337/diabetes.53.8.2169

10.1111/j.1572-0241.2005.41583.x

10.1002/hep.21641

10.1111/j.1478-3231.2006.01315.x

10.1002/hep.21006

10.1053/jlts.2001.23011

10.1007/s00125-005-1948-3

10.1007/s00109-006-0105-x

10.1210/jc.2004-2479

10.1016/j.jhep.2007.01.028

Yki-Jarvinen H. Prediction and prevention of non-insulin-dependent diabetes mellitus. In: Williams G Pickup J eds. Textbook of Diabetes. 2001; 2 ed. Oxford: Blackwell 83.1–83.13.

Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol. 45:879–881 2006; author reply 881–882.

10.1055/s-0038-1650524

10.1016/j.jhep.2006.02.011

10.1111/j.1572-0241.2005.41500.x

10.1530/eje.1.01821

10.1373/clinchem.2006.067397

10.1002/hep.20280

10.2337/diacare.29.04.06.dc05-1938

10.2337/dc06-2342

Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006; 44: 27–33.

10.1053/gast.2001.25540

10.1038/oby.2002.137

10.1177/135965350300800303

10.1002/hep.20092

10.1016/S1542-3565(04)00457-4

10.1016/j.cgh.2006.09.025